1. Medtech Insight
  2. >>Geography
  3. >>North America
  4. >>United States

Wireless Technology And The Rise Of “Anywhere” Monitoring

The emerging market for wireless and remote monitoring technologies comes at a time when providers are looking for new tools to not only keep patients out of the hospital, but also to prevent unnecessary readmissions. These goals, along with a growing list of enabling technologies in the pipeline, are helping drive health care toward an era of unprecedented connectivity – one in which physicians and other care givers are able to monitor and even treat patients whenever needed wherever they may be – a shift that many believe will profoundly change health care as we know it.

The health care industry is still in the early stages of a technological revolution involving wireless and remote technology; however, the changes that have already taken place have been profound. Most young physicians today – as well as those still in medical school – will never know a way of practicing medicine that does not include wireless, mobile devices such as smartphones and tablets. In fact, there is substantial interest among physicians in using wireless devices to perform a variety of clinical tasks, according to a survey conducted in 2010. (See Exhibit 1.) But for all the changes that have already occurred, there are even more pioneering ideas that continue to push their way into the spotlight as device manufacturers, software developers, and other innovators look for the right tools to address health care’s most pressing needs.

Some of the first innovations are coming from companies developing wireless, remote monitoring technology, which has emerged as a tool that could offer important advantages, not only for patient care...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

FDA Halts Acceptance Of Chinese Lab Data Due To Accuracy Issues

 
• By Elizabeth Orr

The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

More from North America

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financial Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Debate On FDA User Fee Reauthorization Begins To Take Shape

 
• By Elizabeth Orr

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.